The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Open accessAbstract
Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of population and according to the World Health Organization (WHO) the number of adults living with diabetes is expected to increase. Since type 2 diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 90–95%) and often the mono-target therapy fails in managing blood glucose levels and the other comorbidities, this review focuses on the potential drugs acting on multi-targets involved in the treatment of this type of diabetes. In particular, the review considers the main systems directly involved in T2DM or involved in diabetes comorbidities. Agonists acting on incretin, glucagon systems, as well as on peroxisome proliferation activated receptors are considered. Inhibitors which target either aldose reductase and tyrosine phosphatase 1B or sodium glucose transporters 1 and 2 are taken into account. Moreover, with a view at the multi-target approaches for T2DM some phytocomplexes are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166 · cited 1×
“These findings have supported the relative contributions between insulin resistance and β-cell dysfunction to the pathophysiology of T2DM [22].”
BackgroundPrevalence of impaired glucose tolerance among children and adolescents with marked obesity
Sinha, R., Fisch, G., Teague, B., Tamborlane, W. V., Banyas, B., Allen, K., Savoye, M., Rieger, V., Taksali, S., Barbetta, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012578 · Cited by 1,709 · cited 1×
“The studies carried out on children demonstrated the co-existence of obesity, insulin resistance, and β-cell dysfunction as observed in older T2DM patients [9].”
BackgroundRisk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention
Wu, Y., Ding, Y., Tanaka, Y., & Zhang, W. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.10001 · Cited by 1,279
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Emerging epidemic of type 2 diabetes in youth
Rosenbloom, A. L., Joe, J. R., Young, R. S., & Winter, W. E. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.345 · Cited by 1,019 · cited 1×
“Indeed, in the past two decades, T2DM emerged as a new and very serious health problem also in children [7,8].”
BackgroundControl of Inflammation, Cytokine Expression, and Germinal Center Formation by BCL-6
Dent, A. L., Shaffer, A. L., Yu, X., Allman, D., & Staudt, L. M. (1997) · Science · doi:10.1126/science.276.5312.589 · Cited by 945
Genomics, type 2 diabetes, and obesity
McCarthy, M. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906948 · Cited by 938
Obesity: definition, comorbidities, causes, and burden.
Apovian, C. M. (2016) · PubMed · Cited by 898
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“Several in vivo studies show promising results in terms of decreasing glycated hemoglobin and weight loss in both healthy subjects and patients with T2DM [46].”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“Furthermore, the modifications could include substitution with Lys40 that allows site-specific lipidation or PEGylation of the peptide in order to avoid DPP-4 inactivation and consequently to permit less frequent administrations [45].”
BackgroundNarrative Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications
Kelesidis, T., Kelesidis, I., Chou, S., & Mantzoros, C. S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00008 · Cited by 666
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
The role of fatty acids in insulin resistance
Sears, B., & Perry, M. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0123-1 · Cited by 548
Assessing obesity: classification and epidemiology
Seidell, J. C., & Flegal, K. M. (1997) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011611 · Cited by 499
Gut microbiome and type 2 diabetes: where we are and where to go?
Sharma, S., & Tripathi, P. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.10.003 · Cited by 428
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia
Xu, G., Kaneto, H., Laybutt, D. R., Duvivier-Kali, V. F., Trivedi, N., Suzuma, K., King, G. L., Weir, G. C., & Bonner-Weir, S. (2007) · Diabetes · doi:10.2337/db06-1033 · Cited by 377
Ali, O. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i4.114 · Cited by 350 · cited 1×
“Furthermore, several risk factors are associated with T2DM: Genetic influences Genetics play a very strong role in the development of T2DM [23].”
BackgroundBoden, G. (2003) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2003-39781 · Cited by 348 · cited 1×
“Elevated plasma FFA concentrations are associated with increased liver production and secretion of glucose [17].”
BackgroundSedentary lifestyle and risk of obesity and type 2 diabetes
Hu, F. B. (2003) · Lipids · doi:10.1007/s11745-003-1038-4 · Cited by 302
TYPE 2 DIABETES MELLITUS IN MINORITY CHILDREN AND ADOLESCENTS
Dabelea, D., Pettitt, D. J., Jones, K. L., & Arslanian, S. A. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70098-0 · Cited by 276
The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
Meek, C. L., Lewis, H. B., Reimann, F., Gribble, F. M., & Park, A. J. (2016) · Peptides · doi:10.1016/j.peptides.2015.08.013 · Cited by 269
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Tenenbaum, A., Motro, M., & Fisman, E. Z. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-14 · Cited by 246
The role of leptin in leptin resistance and obesity
Zhang, Y., & Scarpace, P. J. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.05.038 · Cited by 244
Zambrowicz, B., Freiman, J., Brown, P. M., Frazier, K. S., Turnage, A., Bronner, J., Ruff, D., Shadoan, M., Banks, P., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 243
Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
Liu, J. (., Lee, T., & DeFronzo, R. A. (2012) · Diabetes · doi:10.2337/db12-0052 · Cited by 225
An Overview of Herbal Products and Secondary Metabolites Used for Management of Type Two Diabetes
Ota, A., & Ulrih, N. P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00436 · Cited by 216
Guerre-Millo, M. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03344048 · Cited by 209
The role of leptin in leptin resistance and obesity
Enriori, P. J., Evans, A. E., Sinnayah, P., & Cowley, M. A. (2006) · Obesity · Cited by 197
PPAR dual agonists: Are they opening Pandora's Box?
BALAKUMAR, P., ROSE, M., GANTI, S., KRISHAN, P., & SINGH, M. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.03.002 · Cited by 190
Precision medicine in the management of type 2 diabetes
Gloyn, A. L., & Drucker, D. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30052-4 · Cited by 183
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Ahmed, I., Adeghate, E., Cummings, E., Sharma, A. K., & Singh, J. (2004) · Molecular and Cellular Biochemistry · doi:10.1023/b:mcbi.0000028738.95518.90 · Cited by 168
McGovern, A., Tippu, Z., Hinton, W., Munro, N., Whyte, M., & de Lusignan, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13160 · Cited by 166
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159
The emerging genetics of type 2 diabetes
Bonnefond, A., Froguel, P., & Vaxillaire, M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.06.004 · Cited by 153
Glucagon and Type 2 Diabetes: the Return of the Alpha Cell
Lund, A., Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0555-4 · Cited by 144
Peroxisome Proliferator-Activated Receptors and the Control of Inflammation
Cabrero, À., Laguna, J. C., & Vázquez‐Carrera, M. (2002) · Current Drug Targets - Inflammation & Allergy · doi:10.2174/1568010023344616 · Cited by 143
Day, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science · doi:10.1002/bip.22072 · Cited by 133
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 133
Piteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130
Genetics of Type 2 Diabetes: Insights into the Pathogenesis and Its Clinical Application
Sun, X., Yu, W., & Hu, C. (2014) · BioMed Research International · doi:10.1155/2014/926713 · Cited by 124
Ogata, T., Miyauchi, T., Sakai, S., Irukayama‐Tomobe, Y., Goto, K., & Yamaguchi, I. (2002) · Clinical Science · doi:10.1042/cs103s284s · Cited by 115
Pourcet, B., Fruchart, J., Staels, B., & Glineur, C. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.379 · Cited by 113
Parker, J. A., McCullough, K. A., Field, B. C. T., Minnion, J. S., Martin, N. M., Ghatei, M. A., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.227 · Cited by 111
Lee, H. J., Lee, Y., Park, S. K., Kang, E. S., Kim, H.-J., Lee, Y. C., Choi, C. S., Park, S. E., Ahn, C. W., Soo, B., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.03.015 · Cited by 107
Precision medicine in diabetes prevention, classification and management
Xie, F., Chan, J. C. N., & Ronald, C. W. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12830 · Cited by 103
Sridhar, M. G., Vinayagamoorthi, R., Suyambunathan, V. A., Bobby, Z., & Selvaraj, N. (2007) · British Journal Of Nutrition · doi:10.1017/s000711450783176x · Cited by 102
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Asmar, M., Tangaa, W., Madsbad, S., Hare, K. J., Astrup, A. V., Flint, A., Bülow, J., & Holst, J. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00639.2009 · Cited by 91
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 82
Extracts of Momordica charantia Suppress Postprandial Hyperglycemia in Rats
Uebanso, T., Arai, H., Taketani, Y., Fukaya, M., Yamamoto, H., Mizuno, A., Uryu, K., Hada, T., & Takeda, E. (2007) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.53.482 · Cited by 82
Genes, Genetics, and Environment in Type 2 Diabetes: Implication in Personalized Medicine
Kaul, N., & Ali, S. (2015) · DNA and Cell Biology · doi:10.1089/dna.2015.2883 · Cited by 78
Yadav, A., jyoti, P., Jain, S. K., & Bhattacharjee, J. (2011) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-011-0119-1 · Cited by 77
Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-1514 · Cited by 74
Physiological role of adiponectin in different tissues: a review
Esmaili, S., Hemmati, M., & Karamian, M. (2018) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1493606 · Cited by 73
Bhat, V. K., Kerr, B. D., Vasu, S., Flatt, P. R., & Gault, V. A. (2013) · Diabetologia · doi:10.1007/s00125-013-2892-2 · Cited by 66
Irwin, N., & Flatt, P. R. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i15.1285 · Cited by 64
Busch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 63
Bariatric surgery and obesity: influence on the incretins
Laferrère, B. (2016) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2016.8 · Cited by 57
Lu, Y., Griffen, S. C., Boulton, D. W., & Leil, T. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00274 · Cited by 54
Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors
Chepurny, O. G., Bonaccorso, R. L., Leech, C. A., Wöllert, T., Langford, G. M., Schwede, F., Roth, C. L., Doyle, R. P., & Holz, G. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-22106-1 · Cited by 54
Maccari, R., CORSO, A. D., Paoli, P., Adornato, I., Lori, G., Balestri, F., Cappiello, M., Naß, A., Wolber, G., & Ottanà, R. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.10.024 · Cited by 54
Mollah, M. L., Kim, G., Moon, H., Chung, S., Cheon, Y., Kim, J., & Kim, K. (2008) · Phytotherapy Research · doi:10.1002/ptr.2593 · Cited by 53
Jalovaara, K., Santaniemi, M., Timonen, M., Jokelainen, J. J., Kesäniemi, Y. A., Ukkola, O. H., Keinanen-Kiukaanniemi, S. M., & Rajala, U. (2008) · Metabolism · doi:10.1016/j.metabol.2008.03.019 · Cited by 50
Esposito, K., Mosca, C., Brancario, C., Chiodini, P., Ceriello, A., & Giugliano, D. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.590127 · Cited by 47
Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Takano, H., Hasegawa, H., Zou, Y., & Komuro, I. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383719 · Cited by 47
Tai, E. S., Collins, D. E., Robins, S. J., O’Connor, J. J., Bloomfield, H. E., Ordovás, J. M., Schaefer, E. J., & Brousseau, M. E. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.034 · Cited by 44
Hasib, A., Ng, M. T., Khan, D., Gault, V. A., Flatt, P. R., & Irwin, N. (2018) · Peptides · doi:10.1016/j.peptides.2017.10.015 · Cited by 34
Lynch, A. M., Pathak, N., Flatt, Y. E., Gault, V. A., O'Harte, F. P. M., Irwin, N., & Flatt, P. R. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.09.018 · Cited by 27
Design and synthesis of a novel class of dual PPARγ/δ agonists
Gonzalez, I. C., Lamar, J., Iradier, F., Xu, Y., Winneroski, L. L., York, J. S., Yumibe, N. P., Zink, R. W., Montrose‐Rafizadeh, C., Etgen, G. J., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.029 · Cited by 26
Antihypertensive effect of ragaglitazar: A novel PPARα and γ dual activator
Mamnoor, P., Hegde, M. N., Datla, S. S. V., Damarla, R. K. B., RAJAGOPALAN, R., & Chakrabarti, R. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.03.020 · Cited by 22
Pathak, V., Vasu, S., Flatt, P. R., & Irwin, N. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12227 · Cited by 19
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Stefanski, D. A., & Majkowska, L. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.12.1713 · Cited by 3
Cited by
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Dahlén, A. D., Dashi, G., Maslov, I., Attwood, M. M., Jonsson, J., Trukhan, V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807548 · Cited by 275
Computer especially AI-assisted drug virtual screening and design in traditional Chinese medicine
Lin, Y., Zhang, Y., Wang, D., Yang, B., & Shen, Y.-Q. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154481 · Cited by 107
Yale, J.-F., Bodholdt, U., Catarig, A.-M., Catrina, S., Clark, A., Ekberg, N. R., Erhan, U., Holmes, P., Knudsen, S. T., Liutkus, J., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002619 · Cited by 50
Metadata
- Authors
- Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-04-23
- Volume
- 25
- Issue
- 8
- Pages
- 1987
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3019636814
- Cited by
- 494
- References
- 86
- FWCI
- 37.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.